A second-generation "hypoxia in a pill" rescues neurodegenerative phenotypes across distinct mouse models.

A second-generation "hypoxia-in-a-pill" therapy rescues neurodegenerative phenotypes and extends lifespan in multiple mouse models of neurodegeneration.

• Why it matters: Chronic hypoxia shows therapeutic potential but faces practical and safety challenges, highlighting the need for safer, more effective delivery methods for hypoxia-based treatments.
• What they did: Researchers optimized a small-molecule regimen using GBT601 and PT2399, demonstrating rescue of neurodegenerative phenotypes and lifespan extension in mouse models of Leigh syndrome, Friedreich's ataxia, and Parkinson's disease.
• The result: The combination therapy alleviated neurological symptoms, halted disease progression, and reversed motor deficits without adverse effects, supporting further preclinical and clinical evaluation of this "hypoxia in a pill" approach.